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bjectives We sought to evaluate the impact of post-primary percutaneous coronary intervention
PCI) Thrombolysis In Myocardial Infarction (TIMI) ﬂow grades in the infarct-related artery (IRA) in
atients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock.
ackground The clinical implications and correlates of post-procedural TIMI ﬂow grades in patients
ith STEMI and cardiogenic shock treated with primary PCI have not been elucidated.
ethods We evaluated 4,731 STEMI patients with cardiogenic shock undergoing primary PCI at 567
ospitals participating in the American College of Cardiology–National Cardiovascular Database
athPCI Registry to determine the association of post-procedural TIMI ﬂow grades 0 to 2 with in-
ospital outcomes.
esults Post-PCI TIMI ﬂow grades 0 to 2 in the IRA were present in 14.7% of patients. Compared
ith patients with TIMI ﬂow grade 3, those with TIMI ﬂow grades 0 to 2 were more likely to un-
ergo coronary artery bypass graft surgery after PCI (20% vs. 5.4%), and develop renal failure (10.1%
s. 5.1%), cardiac tamponade (1.0% vs. 0.5%), and bleeding requiring blood transfusion (35.2% vs.
1.6%). Unadjusted mortality was more than 2-fold higher with TIMI ﬂow grades 0 to 2 versus TIMI
ow grade 3 (63% vs. 27%). There was a graded inverse relationship with TIMI ﬂow in the IRA and
he adjusted mortality (odds ratio [OR] for TIMI ﬂow grades 0/1: 5.47 [95% conﬁdence interval (CI):
.13 to 7.24] and for TIMI ﬂow grade 2: 2.63 [95% CI: 2.02 to 3.42] compared with TIMI ﬂow grade
). Our study also identiﬁed factors associated with post-PCI TIMI ﬂow grades 0 to 2.
onclusions Lack of procedural success (post-PCI TIMI ﬂow grades 0 to 2 in the IRA) after primary
CI for STEMI among patients with cardiogenic shock is associated with a much higher risk of mor-
ality compared with the risk for patients with normal post-PCI TIMI ﬂow grade 3. (J Am Coll Car-
iol Intv 2009;2:56–64) © 2009 by the American College of Cardiology Foundation
rom the *Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina; †Sutter Pacific Heart
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57hrombolysis In Myocardial Infarction (TIMI) flow grades
ave been shown to have significant prognostic implication
mong patients undergoing reperfusion therapy for ST-
egment elevation myocardial infarction (STEMI) (1–3).
oth short- and intermediate-term outcomes have been
hown to be significantly higher among patients with TIMI
ow grades 0 to 2 following reperfusion than in those with
IMI flow grade 3 (1,2,4–6). Because of its significant
elevance to the overall outcomes among patients receiving
eperfusion therapy for STEMI, multiple investigations
ave focused on describing risk factors and strategies to
inimize TIMI flow grades 0 to 2 following reperfusion
7–13).
Some studies have reported higher incidence of TIMI flow
rades 0 to 2 in STEMI patients with cardiogenic shock (14)
ompared with that reported by others in STEMI patients
ithout cardiogenic shock (2,7–9). However, these studies
ere generally small and/or involved selected patient popula-
ions and the true incidence of TIMI flow grades 0 to 2 in
TEMI patients with cardiogenic shock is currently not
nown. Furthermore, the clinical correlates and implications of
IMI flow grades in patients with STEMI complicated by
ardiogenic shock are less well studied.
Accordingly, the goal of the current investigation was to
escribe the incidence, clinical features, and outcomes of
atients with STEMI and presenting with cardiogenic shock
ndergoing primary percutaneous coronary interventions
PCI) who have post-procedural TIMI flow grades 0 to 2
ompared with the incidence, clinical features, and outcomes of
atients with normal TIMI flow grade 3 in the infarct-related
rtery (IRA).
ethods
tudy population. Data from 708,481 consecutive patients
ndergoing PCI at 638 hospitals in the U.S. were entered
nto the American College of Cardiology–National Cardio-
ascular Database Registry (ACC-NCDR) between January
, 2004, and March 30, 2007. Details of this registry have
een previously published (15). Participation in ACC-
CDR was subject to the approval of the institutional
eview board of each hospital. As patient information was
ollected anonymously without unique patient identifiers,
ndividual informed consent was not required.
We included patients with STEMI and cardiogenic
hock (n  7,070). From this cohort, we excluded those
reated with fibrinolysis (n 396), those transferred in from
nother facility for primary PCI (n 1,928), and those with
issing information on post-PCI TIMI flow grades (n 
5). The final study population consisted of 4,731 patients
reated at 567 hospitals. We did not exclude the small
roportion of patients arriving 24 h from symptom onset
s ACC/American Heart Association guidelines for
TEMI recommends invasive strategy as class I indication ap to 36 h from symptom onset in patients with STEMI
nd cardiogenic shock (16).
ata deﬁnitions. Hospital characteristics and patient-level
ata, including demographic, clinical, angiographic, and
rocedural variables, were collected retrospectively via a
tandardized set of data elements and definitions that are
vailable on the ACC-NCDR website (15). Data on
eriprocedural medications were collected before or during
rocedure (combined) and at discharge. Cardiogenic shock
as defined as systolic blood pressure 80 mm Hg and/or
ardiac index 1.8 l/min/m2 despite maximal treatment or
ntravenous inotropes and/or intra-aortic balloon pump
ecessary to maintain systolic blood pressure 80 mm Hg
nd/or cardiac index 1.8 l/min/m2. Infarct-related artery
as defined as the first artery treated during primary PCI for
hese patients. The TIMI flow grades in the IRA were
etermined both before and after PCI by the treating
hysicians and ascertained for the present study from that
ntered in the data collection
orm by participating sites. The
se of medications in the
eriprocedural period as well as
nterventional strategies were
ot outlined specifically in
CC-NCDR and left to the
iscretion of the operator, but
xpected to be in accordance
ith the ACC/American Heart
ssociation guidelines (16).
tatistical analyses. Continuous
ariables are presented as medi-
ns with 25th and 75th percen-
iles. Categorical variables are
xpressed as frequencies with
ercentages. Comparisons be-
ween the 2 groups (patients
ith and without TIMI flow grade 3 after the procedure)
ere made using Mann-Whitney U and Wilcoxon rank
um tests for continuous variables and Pearson chi-square
est for categorical variables. Mortality—overall and during
nd after cardiac catheterization in various TIMI flow
rades—was examined. Several sensitivity analyses were also
erformed. Thus, we examined the relationship of TIMI
ow grade with this outcome: 1) excluding patients who
ied in cardiac catheterization laboratory (in whom early
eath may have precluded completion of the diagnostic
nd/or the PCI procedure); 2) restricting our population to
nly those who received coronary stents (to account for the
omplexity of the coronary anatomy in patients with shock
hat would have posed significant difficulty in deploying
tents in the IRA); 3) restricting our population to those
ndergoing single vessel PCI to eliminate the error of
isclassification of the IRA as defined in the current study;
Abbreviations
and Acronyms
ACC-NCDR  American
College of Cardiology–
National Cardiovascular
Database Registry
CABG  coronary artery
bypass graft surgery
IRA  infarct-related artery
PCI  percutaneous
coronary interventions
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionnd 4) in patients whose ages were 75 and 75 years.
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58A multivariable logistic regression model was used to
djust for the influence of baseline confounders on mortal-
ty. The generalized estimating equation method with
xchangeable working correlation structure was used to
ccount for within-hospital clustering, because patients at
he same hospital are more likely to have similar responses
elative to patients in other hospitals (i.e., within-center
orrelation for response) (17). The exchangeable structure
ssumes that any 2 distinct patients from the same hospital
ave the same correlation coefficient. The method produces
stimates similar to those from ordinary logistic regression,
ut the estimated variances of the estimates are adjusted for
he correlation of outcomes within each hospital. Variables
djusted in the model were age, sex, race, family history of
oronary artery disease, body mass index, hypertension,
iabetes mellitus, dyslipidemia, peripheral vascular disease,
erebrovascular disease, prior myocardial infarction, prior
CI, prior coronary artery bypass grafting (CABG), renal
nsufficiency or creatinine 2 mg/dl at baseline, smoking
tatus, time of symptom onset to arrival, signs of congestive
eart failure at the time of admission, New York Heart
ssociation functional class, and time from symptom onset
o arrival. Additionally, angioplasty variables adjusted in the
odel included door-to-balloon time, multivessel disease,
ultivessel PCI, lesion location, lesion in graft, and pre-
rocedure TIMI flow grade. Adjusted mortality was also
xamined in various TIMI flow rates after restricting our
atient population to those 12 h from symptom onset to
ospital arrival.
For the determination of factors associated with TIMI flow
rades 0 to 2, baseline variables and angioplasty variables were
ntered into a multivariable model. In addition, generalized
stimating equation models were again used to adjust for
orrelations within hospital correlations. Wald chi-square sta-
istic was used to determine the relative significance of the
actors associated with TIMI flow grades 0 to 2. The C statistic
as calculated to assess model discrimination. Finally, factors
ssociated with TIMI flow grades 0 to 2 were also examined
fter restricting the patients to those arriving at the hospital
ithin 12 h of their symptom onset.
A p value 0.05 was considered significant for all tests.
ll statistical analyses were performed using SAS software,
ersion 9.0 (SAS Institute, Cary, North Carolina).
esults
IMI ﬂow grades: incidence and clinical and angiographic
haracteristics. Of 4,731 patients with cardiogenic shock
ho underwent primary PCI, post-procedure TIMI flow
rades 0, 1, 2, and 3 occurred in 229 (4.8%), 125 (2.6%),
42 (7.2%), and 4,035 (85.3%) patients, respectively. Ex-
luding death in cardiac catheterization laboratory, these
ates were observed in 169 (3.7%), 97 (2.1%), 307 (6.8%),
nd 3,952 (87.3%) of patients, respectively. Compared with (atients who had TIMI flow grade 3, those with TIMI flow
rades 0 to 2 were older with no significant difference in
ther demographic features including gender, race, and
ody mass index (Table 1). These patients were also more
ikely to have a history of hypertension, diabetes, cerebro-
ascular disease, and prior CABG and have signs of con-
estive heart failure at the time of presentation. Patients
ith TIMI flow grades 0 to 2 were also likely to present
ater after their symptom onset and have a higher serum
reatinine before their procedure. In contrast, these patients
ere significantly less likely to be current smokers or have a
istory of chronic lung disease.
Median door-to-balloon time was longer and fewer
atients with TIMI flow grades 0 to 2 received primary PCI
ithin 90 min of their hospital arrival (Table 2). Pre-
rocedural TIMI flow grade 0 and multivessel coronary
isease were significantly more frequent among patients
ith TIMI flow grades 0 to 2 than in those who had TIMI
ow grade 3. The location of the IRA was more commonly
he left main or left anterior descending arteries or saphe-
ous vein graft in patients with TIMI flow grades 0 to 2.
hese patients also had a lower median left ventricular
jection fraction and had more dissection of coronary
rteries after the procedure. The median fluoroscopy time
as also longer in the patients with TIMI flow grades 3.
edical treatments and in-hospital events. The use of aspi-
in, clopidogrel, and glycoprotein IIb/IIIa was significantly
ower in patients with TIMI flow grades 0 to 2, whereas the
se of most other treatments was not significantly different
etween the 2 groups. In contrast, intra-aortic balloon pump
se was 1.3-fold higher, and CABG was 4-fold higher
mong patients with TIMI flow grades 0 to 2 (Table 3).
Many in-hospital adverse events were significantly higher
mong patients with TIMI flow grades 0 to 2. Thus, renal
ailure and cardiac tamponade was 2-fold higher and need
or blood transfusion was 1.6-fold higher in patients with
han in those without TIMI flow grades 0 to 2. In
articular, in-hospital mortality was 2.3-fold higher with
ne-third of deaths occurring early, that is, in the cardiac
atheterization laboratory, in patients with TIMI flow
rades 0 to 2. Median time to death was 1 day earlier in
hese patients than in those with TIMI flow grade 3. Even
fter exclusion of patients who died in the cardiac catheter-
zation laboratory, in-hospital mortality was higher among
hose with TIMI flow grades 0 to 2 (53.6% vs. 25.3%, p 
.0001). Similarly, when we excluded patients with inade-
uate IRA PCI results (dissection, percentage of stenosis
50, or immediate need for CABG), the relationship
etween post-procedural TIMI flow and outcomes did not
hange (58.3% and 26.5% in patients with post-procedural
IMI flow grades 3 vs. 3). Mortality was also higher
mong stented patients with TIMI flow grades 0 to 2
ompared with mortality in those with TIMI flow grade 3
51.2% vs. 24.6%, p  0.0001).
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59In-hospital mortality was inversely related to TIMI flow
ates, decreasing significantly from TIMI flow grades 0/1 to 2,
nd was lowest among those with TIMI flow grade 3 after the
rocedure (Fig. 1). This relationship persisted even after
xclusion of patients who died in the cardiac catheterization
aboratory (in-hospital death: 54.7%, 65.0%, 49.6%, and 25.3%
ith TIMI flow grades 0, 1, 2, and 3, respectively) and in
atients with single-vessel (in-hospital death: 66.3%, 70.9%,
3.2%, and 25.3% with TIMI flow grades 0, 1, 2, and 3,
espectively) or multivessel (in-hospital death: 81.5%, 86.4%,
7.4%, and 42.6% with TIMI flow grades 0, 1, 2, and 3,
espectively) PCI. Albeit, mortality was higher for each post-
rocedural TIMI flow in the multivessel PCI cohort than in
hose only undergoing infarct-artery PCI. Additionally, a
imilar inverse relationship was observed among patients with
IMI flow grades 2 or 3 before PCI with mortality of 54.4%
nd 29.3% in those with post-procedural TIMI flow grades
3 and 3, respectively. TIMI flow grades 0 to 2 remained an
Table 1. Baseline Clinical Characteristics
Variables Overall
n, % 4,731 (100)
Demographics
Age, median (IQR), yrs 64 (55–74)
Age 75 yrs, % 24.7
Weight, median (IQR), kg 80 (69–93)
Height, median (IQR), cm 173 (163–178)
Body mass index, median (IQR), kg/m2 27 (24–31)
Females, % 35.4
Caucasians, % 84.6
Medical history
Prior myocardial infarction, % 21.6
Smoker—current, % 40.6
Hypertension, % 60.6
Hyperlipidemia, % 50.9
Diabetes mellitus, % 25.5
Peripheral vascular disease, % 10.3
Cerebrovascular disease, % 10.3
Prior coronary artery bypass surgery, % 7.0
Prior percutaneous coronary intervention, % 18.4
Prior congestive heart failure, % 9.5
Chronic lung disease, % 17.8
Renal failure or dialysis, % 6.9
Last serum creatinine, median (IQR), mg/dl 1.2 (1.0–1.5)
Symptoms of heart failure at presentation, % 30.0
Time from symptom onset to hospital arrival, %
0 to 6 h 82.7
6 to 12 h 7.7
12 to 24 h 3.8
24 h to 7 days 5.3
IQR interquartile range; TIMI Thrombolysis In Myocardial Infarction.ndependent correlate of in-hospital mortality after adjust- Tents for baseline confounding (odds ratio [OR]: 3.72, 95%
onfidence interval [CI]: 3.07 to 4.51, p  0.001 vs. TIMI
ow grade 3). A graded inverse relationship was observed in
atients between TIMI flow grades 0/1 (OR: 5.47, 95% CI:
.13 to 7.24) and 2 (OR: 2.63, 95% CI: 2.02 to 3.42) and
djusted mortality when compared with patients with TIMI
ow grade 3. Even when we restricted our population to those
atients with symptom onset to hospital arrival time 12 h,
he inverse relationship between TIMI flow grade and in-
ospital mortality persisted (TIMI flow grades 0/1 OR: 6.25,
5% CI: 4.61 to 8.47 and TIMI flow grade 2 OR: 2.63, 95%
I: 1.99 to 3.48 [referent TIMI flow grade 3]). Furthermore,
his inverse relationship between TIMI flow grade and in-
ospital mortality was present in patients 75 years as well as
75 years of age, with higher mortality for each flow grade in
he older cohort (Fig. 2).
linical correlates of post-primary PCI TIMI ﬂow grades 0
o 2. Independent factors associated with post-procedural
TIMI Flow Grade
p Value0–2 3
696 (14.7) 4,035 (85.3)
67 (57–78) 63 (54–74) 0.0001
31.6 23.5 0.0001
80 (68–93) 81 (69–93) 0.7228
173 (163–178) 173 (163–178) 0.4027
27 (24–31) 27 (24–31) 0.6554
35.8 35.3 0.8049
82.0 85.0 0.0783
23.0 21.3 0.3285
31.2 42.3 0.0001
64.8 59.8 0.0132
45.8 51.7 0.0041
28.9 24.9 0.0264
10.6 10.3 0.7811
12.5 9.9 0.0381
9.6 6.5 0.0027
17.8 18.5 0.6725
8.8 9.6 0.4791
13.2 18.6 0.0006
8.1 6.7 0.1846
1.3 (1.0–1.6) 1.2 (1.0–1.5) 0.0001
35.9 29.0 0.0002
0.0001
76.0 83.9
8.5 7.5
5.5 3.5
8.9 4.7IMI flow are shown in Table 4 (model C statistic: 0.67).
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60ven when we restricted our analysis to patients presenting
o the hospital within 12 h of their symptom onset, the
linical correlates of TIMI flow grades 0 to 2 remained the
ame (data not shown).
iscussion
ur study ﬁndings. Our findings suggest that suboptimal
oronary flow (TIMI flow grades 0 to 2) occurs in up to 1
n 7 patients with cardiogenic shock undergoing primary
CI and has a significant impact on the prognosis of these
atients. Those with TIMI flow grades 0 to 2 have up to
-fold higher risk for in-hospital complications including
ardiac tamponade, renal failure, and blood transfusion.
trikingly, the in-hospital mortality occurred in two-thirds
Table 2. Angiographic Variables
Variable Overall
n, % 4,731 (100)
Door-to-balloon time, median (IQR), min 88 (64–12
Door-to-balloon time 90 min, % 48.7
Angiographic factors
No. of narrowed coronary arteries (50% stenosis)
1 36.0
2 33.9
3 29.5
Infarct-related artery
Left main 2.4
Left anterior descending 40.6
Left circumﬂex 12.9
Right 43.8
SVG 3.2
Multivessel PCI (1 vessel), % 10.9
Pre-PCI TIMI ﬂow of the infarct-related artery
0 70.5
1 11.6
2 9.3
3 8.2
Ejection fraction, median (IQR), % 40 (28–50
Post-PCI TIMI ﬂow of the infarct-related artery
0 4.8
1 2.6
2 7.2
3 85.3
Final infarct artery stenosis, median (IQR), % 0 (0–0)
Stent implantation, % 85.7
Stent implantation excluding patients who died in the
cardiac catheterization laboratory, %
87.4
Dissection of infarct artery, % 2.4
Fluoroscopy time, median (IQR), min 14 (9–21)
PCI percutaneous coronary intervention; SVG saphenous vein graft; other abbreviations as in Tf patients with TIMI flow grades 0 to 2 and was 2.3-fold wigher than in patients with TIMI flow grade 3 and
emained independently related to mortality even after
ccounting for baseline confounders. Although approxi-
ately one-third of the deaths in these patients occurred in
he catheterization laboratory, the majority occurred after
he procedure. Furthermore, an inverse relationship was
een between in-hospital mortality and TIMI flow grades
ith mortality decreasing significantly as flow rates in-
reased from TIMI flow grades 0 and 1 to 3. Even when we
xcluded deaths in the cardiac catheterization laboratory
hat may not have permitted sufficient time for the use of
tents or therapeutic agents (antithrombotics and micro-
ascular vasodilators such as adenosine) to improve coro-
ary flow, or when we restricted our patients to those
resenting 12 h from their symptom onset, or to those
TIMI Flow Grade
p Value0–2 3
696 (14.7) 4,035 (85.3)
93 (66–131) 88 (63–120) 0.0145
52.7 48.0 0.0020
0.0001
28.5 37.3
35.9 33.5
35.2 28.5
0.0001
5.5 1.8
45.8 39.7
13.4 12.9
35.2 45.3
5.8 2.8 0.0001
15.5 10.1 0.0001
0.0001
80.0 68.9
11.1 11.7
5.3 9.9
3.6 9.0
35 (20–45) 40 (30–50) 0.0001
32.9 0
18.0 0
49.1 0
0 100
20 (0–100) 0 (0–0) 0.0001
54.0 91.2 0.0001
59.0 91.5 0.0001
4.5 2.0 0.0001
16 (10–25) 13 (9–21) 0.00011)
)ho received stents, the inverse relationship between post-
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61rocedural TIMI flow grades and mortality persisted. Fi-
ally, our data also provide insight into the clinical, angio-
raphic, and treatment factors independently associated
ith TIMI flow grades 0 to 2 in STEMI patients with
ardiogenic shock undergoing primary PCI.
omparisons with prior studies. Similar to our findings, the
ew studies that have reported TIMI flow grades after
rimary PCI in patients with cardiogenic shock have sug-
ested higher TIMI flow grades 0 to 2 in these patients
ompared with that seen in patients without cardiogenic
hock undergoing primary PCI (18,19). Only 1 prior study
as reported the relationship between TIMI flow grade after
rimary PCI and in-hospital mortality in these patients.
eymer et al. (19) evaluated predictors of in-hospital
ortality in 1,333 patients with acute myocardial infarction
omplicated by cardiogenic shock treated with primary PCI
etween 1994 and 2001. They showed that mortality
ecreased as TIMI flow grades increased (78%, 66%, and
7% in patients with TIMI flow grades 0/1, 2, and 3,
espectively), a finding similar to that seen in our study.
dditionally, they demonstrated that on multivariate anal-
sis, TIMI flow grades 0 to 2 were independently associated
Table 3. Medical Treatments and In-Hospital Events
Variable
Overa
(n  4,731
Treatment before admission or in periprocedural period
Aspirin, % 82.5
Beta-blockers, % 56.7
Clopidogrel or ticlopidine, % 52.1
Unfractionated heparin or low-molecular weight heparin, % 88.2
Thrombin inhibitors, % 11.7
Glycoprotein IIb/IIIa antagonists, % 77.7
Statins, % 29.2
Intra-aortic balloon pump 52.3
Coronary artery bypass surgery* 7.1
In-hospital events
Stroke/transient ischemic attacks 1.6
Cardiac tamponade 0.6
Renal failure 5.7
Bleeding complications
Any 11.1
Retroperitoneal 0.9
Transfusion—post-procedure 23.2
Death, % 32.3
Death in cardiac catheterization laboratory, % 5.0
Death beyond cardiac catheterization laboratory, % 27.3
Time from hospital arrival to death, median (IQR), days 3.0 (1.0
Post-procedure length of stay, median (IQR), days 6.0 (3.0
*Related to complications of the procedure or multivessel coronary disease requiring revasculariza
Abbreviations as in Table 1.ith increased mortality (OR: 3.4, 95% CI: 2.4 to 4.8). ThisFigure 1. TIMI Flow Grade and Mortality
Post-procedural TIMI ﬂow grades in patients with cardiogenic shock under-
going primary percutaneous coronary interventions and in-hospital death.
Cathlab  cardiac catheterization laboratory; TIMI  Thrombolysis In Myo-ll
, 100%)
TIMI Flow Grade
p Value
0–2
(n  696, 14.7%)
3
(n  4,035, 85.3%)
79.2 83.1 0.0152
50.6 57.8 0.0008
33.2 55.4 0.0001
86.3 88.5 0.0882
11.0 11.8 0.5426
67.1 79.5 0.0001
26.6 29.7 0.0985
64.4 50.3 0.0001
20.0 5.4 0.0001
1.8 1.6 0.7174
1.0 0.5 0.2046
10.1 5.1 0.0001
13.3 10.8 0.0925
1.2 0.9 0.4898
35.2 21.6 0.0001
63.0 27.0 0.0001
20.3 2.3 0.0001
42.7 24.7 0.0001
–7.0) 2.0 (1.0–6.0) 4.0 (1.0–8.0) 0.0028
–10.0) 4.0 (1.0–10.0) 6.0 (4.0–10.0) 0.0001
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62tudy and our investigation not only clearly suggest ex-
remely grave prognosis with TIMI flow grades 0 to 2 for
atients with cardiogenic shock, but also provide quantita-
ive insights into this association in patients with cardio-
enic shock.
The rate of TIMI flow grades 0 to 2 observed in our study
mong patients with cardiogenic shock undergoing primary
CI is twice as high as that reported after primary PCI in
atients with STEMI without cardiogenic shock (2,7–
,20). In addition, these studies and our findings also
uggest that although TIMI flow grades 0 to 2 are adversely
elated to mortality in STEMI patients undergoing primary
Figure 2. Age, TIMI Flow Grade, and Mortality
Post-procedural TIMI ﬂow grades in patients age 75 years versus 75
years and in-hospital death with cardiogenic shock undergoing primary
percutaneous coronary interventions. Abbreviation as in Figure 1.
Table 4. Independent Correlate of Post-Procedural TIMI Flow Grades 0 to 2
Variable Chi-Square
Pre-procedural TIMI ﬂow grade 0 (vs. other) 35.35
Infarct artery segment (vs. other) 27.00
Left main
LAD
Symptom onset to hospital arrival (vs. 6 h) 18.10
6 to 12 h
12 to 24 h
24 h or silent MI
Dyslipidemia 13.74
Age (per 10-yr increase) 11.80
Number of diseased vessels 7.20
2-vessel coronary artery disease
3-vessel coronary artery disease
Bypass vein graft 6.93
Current smoker 3.64
Overall model chi-square 4,750.40
Model C statisticLAD left anterior descending; MImyocardial infarction; other abbreviations as in Tables 1 and 2.CI with or without underlying cardiogenic shock, the
agnitude of this relationship is much greater for patients
ith cardiogenic shock underlying the importance of TIMI
ow grades 0 to 2 in the prognosis of these patients.
linical implications. The reservation in giving glycoprotein
Ib/IIIa and clopidogrel before diagnostic angiography in
ardiogenic shock patients in general is understandable in
iew of higher proportion of these patients that would need
ABG, either because of multivessel disease or mechanical
omplications. However, the opportunity to use these
gents was missed even during the procedure once it was
ecided to proceed with primary PCI (all patients with
ardiogenic shock in this study). Perhaps more frequent use
f glycoprotein IIb/IIIa agents (and clopidogrel) may have
he potential for improving outcomes for these patients
21–23). The importance of decreasing the time from
ymptom onset to hospital arrival as well as of improving
oor-to-balloon time in reducing adverse events cannot be
veremphasized and remains a primary focus of many
ational collaborative initiatives (24). Similarly, greater use
f intra-aortic balloon pumps or other circulatory assist
evices may have the potential for improving coronary flow
nd/or outcomes, especially because intracoronary nitroglyc-
rine, nitroprusside, verapamil, and nicardipine all have the
otential of worsening the hypotension. While intracoro-
ary adenosine may be potentially useful in these patients
nd should be used liberally, the role of administration of
he other agents mentioned in distal coronary bed in
mproving TIMI flow grade and outcomes in shock patients
ithout exacerbating hypotension needs future evaluation.
espite early promise for improving microcirculation,
gents such as l-n-monomethyl-arginine (a nonselective
tients With Cardiogenic Shock Undergoing Primary PCI
Odds Ratio 95% Confidence Interval p Value
2.04 1.61–2.57 0.001
0.001
3.15 1.94–5.13
1.53 1.27–1.86
0.001
1.20 0.90–1.59
1.58 1.04–2.39
2.03 1.51–2.72
0.72 0.60–0.86 0.001
1.14 1.06–1.23 0.001
0.003
1.22 1.00–1.49
1.31 1.07–1.61
2.10 1.21–3.66 0.008
0.83 0.68–1.01 0.056
0.668in Pa
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63itric oxide synthase inhibitor) (25) and a novel anti-
nflammatory agent pexelizumab (a humanized monoclonal
ntibody that binds the C5 component of complement) (26)
ave failed to show any benefits in large phase III clinical
rials, precluding any recommendations for their use. Sim-
larly, thrombectomy and distal protection devices have
ailed to demonstrate unequivocal benefits, and their use
hould at best be individualized at this time (27,28).
Finally, although observational studies have supported
erits of CABG over primary PCI among these patients
29,30), it is unsettled currently if CABG is associated with
etter post-procedural TIMI flow grade in IRA than
rimary PCI for this cohort. The use of CABG in patients
ith multivessel coronary disease and cardiogenic shock has
ome theoretical advantage. Primary PCI has a potential for
istal embolization and slow flow. Additionally, PCI of a
oninfarct artery during the initial procedure may also
ause distal embolization and/or side branch closure, com-
romising collateral circulation to infarct and noninfarct
ones. These problems are less likely with CABG. Future
tudies are needed to determine the best reperfusion strategy
n patients with multivessel coronary disease and cardio-
enic shock.
tudy limitations. This is a retrospective analysis and cau-
ion needs to be exerted while inferring causation. We are
nable to account for the influence of unmeasured con-
ounders on TIMI flow grade and outcomes. We do not
ave information of ST-segment resolution or myocardial
lush score that may have additional prognostic implica-
ions. Additionally, we only have information on in-hospital
utcomes and are unable to provide any insight into the
elationship of TIMI flow grades and long-term outcomes.
onclusions
ur study shows that TIMI flow grades 0 to 2 occur
requently in patients with cardiogenic shock undergoing
rimary PCI and are associated with worse in-hospital
utcomes and higher in-hospital mortality. Our data also
rovide insights into the risk factors for suboptimal coronary
ow and suggest potential strategies for reducing this event.
e believe that physicians will find this information useful
n the risk assessment, treatment, and triaging of patients
ith cardiogenic shock undergoing primary PCI with a
otential for improving their outcomes.
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